Login / Signup

Comparative Treatment Persistence with Bone-Targeting Agents Among Asian Patients with Bone Metastases from Solid Tumors: A Multinational Retrospective Cohort Study.

Chin-Yao ShenPhilip Chun-Ming AuYeon-Hee BaekChing-Lung CheungWei-Pang ChungJu Hwan KimNora J KleinmanTai-Chung LamTzu-Chi LiaoTzu-Chieh LinJu-Young ShinChor-Wing SingIan Chi Kei WongEdward Chia-Cheng Lai
Published in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2022)
Denosumab was associated with a lower risk of interruption than bisphosphonates in patients with bone metastases in Taiwan and Hong Kong. Further investigations may be required to verify patients' actual reasons for discontinuation.
Keyphrases
  • bone mineral density
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • prognostic factors
  • patient reported outcomes
  • drug delivery
  • bone loss